What drugs are not included in a standard drug test panel?

A "standard" drug test — most commonly the federal 5-panel — screens for a specific, limited set of substances. Many drugs of abuse, including fentanyl, benzodiazepines, synthetic cannabinoids, and several others, are not detected unless you deliberately add them to your panel. Understanding this gap is essential before rolling out any testing program.

What the standard 5-panel covers

The 5-panel test screens for five substance classes:

1. Marijuana (THC)
2. Cocaine (COC)
3. Amphetamines (AMP) — includes amphetamine and some panel designs include methamphetamine
4. Opiates (OPI) — targets morphine and codeine; does not reliably detect most synthetic or semi-synthetic opioids
5. Phencyclidine (PCP)

This panel originated with the federal Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines for federal workplace testing. While it remains widely used, its composition reflects a drug landscape that has changed significantly.

Which drugs are commonly missed by standard panels

The following substances are not detected by a standard 5-panel test. Some require dedicated immunoassay strips or expanded multi-panel cups to screen for them:

• Fentanyl and fentanyl analogs — A synthetic opioid that does not cross-react reliably with standard opiate immunoassay reagents. A fentanyl-specific analyte must be added explicitly.
• Benzodiazepines (BZO) — Includes diazepam, alprazolam, clonazepam, and many others. Not part of the 5-panel. A common substance of misuse and a significant clinical concern.
• Oxycodone (OXY) — A semi-synthetic opioid. The standard OPI strip targets morphine/codeine and may not flag oxycodone at clinically meaningful concentrations; a dedicated OXY analyte is required.
• Methadone (MTD) — A synthetic opioid used in medication-assisted treatment and diverted illicitly. Requires its own immunoassay strip.
• Buprenorphine (BUP) — Another medication-assisted treatment drug with diversion potential. Not detected by standard panels.
• MDMA (Ecstasy/Molly) — An empathogen-stimulant. Some AMP reagents may partially cross-react, but dedicated MDMA testing is needed for reliable detection.
• Methamphetamine (MET) — On some 5-panel configurations MET is separate from AMP; verify the specific panel design you're purchasing.
• Barbiturates (BAR) — Sedative-hypnotics that are not included in the federal 5-panel, though they appear on many expanded panels.
• Tricyclic antidepressants (TCA) — Prescription antidepressants with misuse and overdose risk, often included in clinical or pain-management panels but not standard workplace panels.
• K2/Spice (Synthetic Cannabinoids) — THC strips do not detect synthetic cannabinoids. These require a dedicated K2 immunoassay.
• Tramadol — An atypical opioid analgesic that is not captured by standard OPI reagents and requires its own strip.
• Ketamine — A dissociative anesthetic with increasing recreational misuse; not present on standard panels.
• GHB — A central nervous system depressant rarely included in point-of-care panels.
• Kratom — An herbal substance with opioid-like properties that requires a specific immunoassay strip.
• Anabolic steroids — Typically only screened in athletic or specialized programs; not available on most point-of-care instant tests.
• Alcohol (EtG) — Ethanol and its metabolite ethyl glucuronide (EtG) require a separate alcohol strip or dedicated EtG test; they are not part of any standard urine drug panel.
• Nicotine/Cotinine — Screened only when specifically added; not a default analyte on any standard employment panel.
• Xylazine ("tranq") — A veterinary sedative increasingly found in the illicit drug supply; requires a dedicated single-strip test.

Why the gap matters for your program

The original 5-panel was designed for federal workplace compliance and reflects historical patterns of drug misuse. The current drug environment — particularly the prevalence of illicit synthetic opioids, benzodiazepines, and designer drugs — means that a 5-panel alone may leave significant blind spots.

Key considerations when evaluating your panel:

• Industry and regulatory context — DOT-regulated employers are required to use the federal 5-panel for covered employees. Clinical programs, rehab centers, sober-living homes, and pain clinics typically need 10-, 12-, or higher-panel configurations.
• Population and risk profile — Programs serving individuals in medication-assisted treatment should strongly consider adding buprenorphine and methadone analytes to confirm compliance, not just detect misuse.
• Fentanyl exposure risk — Because fentanyl is now commonly found in the illicit supply of many other drugs, many programs are adding fentanyl analytes regardless of the primary substance concern.
• Cutoff levels matter — Even when a drug class is included on a panel, the immunoassay cutoff concentration determines whether a particular dose or usage pattern will register as positive. Review cutoff levels carefully. See our guide to drug test cutoff levels explained for more detail.

Common mistakes when selecting a panel

• Assuming "opiates" means "all opioids" — It does not. The OPI analyte targets morphine and codeine. Fentanyl, oxycodone, methadone, buprenorphine, and tramadol all require separate strips.
• Forgetting about alcohol — Urine drug panels do not detect recent alcohol use unless an EtG or ethanol-specific strip is included.
• Using a 5-panel for clinical or MAT compliance programs — A 5-panel is inadequate for monitoring patients on buprenorphine or methadone therapy, as neither drug appears on a standard 5-panel.
• Not verifying the specific analytes on a multi-panel cup — Panel counts (10-panel, 12-panel, etc.) are not standardized across manufacturers. Always confirm the analyte list before purchasing.
• Overlooking synthetic cannabinoids — K2/Spice does not trigger a THC-positive result. If synthetic cannabinoid use is a concern, it must be an explicitly included analyte.

Recommended products

Magenta offers expanded panels that address many of the gaps described above. Explore these options:

• Specialty single-strip tests — Standalone strips for fentanyl, kratom, cotinine, and more, for programs that need to add one or two analytes to an existing workflow.
• 12-panel drug test cups — Covers a broader range of substances including benzodiazepines, oxycodone, and methadone.
• Oral fluid (saliva) drug tests — An alternative collection method with its own panel configurations.
• Integrated cup category — Browse all integrated-cup options by panel size, including configurations with fentanyl, EtG alcohol, K2, tramadol, kratom, and adulterant checks.